-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tafasitamab in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tafasitamab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Tafasitamab (Monjuvi / Minjuvi)Â is a humanized monoclonal...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Enterocolitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Enterocolitis - Drugs In Development, 2023’, provides an overview of the Enterocolitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Necrotizing Enterocolitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Necrotizing Enterocolitis - Drugs In Development, 2023’, provides an overview of the Necrotizing Enterocolitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Necrotizing Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drugs In Development, 2023’, provides an overview of the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FR-104 in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FR-104 in Kidney Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FR-104 in Kidney Transplant Rejection Drug Details:FR-104 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SB-121
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SB-121 Drug Details SB-121 is under development for the treatment of pervasive developmental disorder...